July 1, 1995Blood Coagulation & Fibrinolysis
Thrombin inhibition in the acute phase of ischaemic stroke using argatroban
Why the study?
Does argatroban reduce D-dimer levels in patients with acute ischaemic stroke?
Population
13 patients with acute ischaemic stroke
Comparison
Argatroban infused continuously at 2.5 mg/h for… vs Placebo. Intravenous glycerol was also…
Follow-up
7 days
Authors
Discussion
Loading...
Member takes
Implication
Argatroban attenuates hypercoagulability in acute ischaemic stroke; extends RCT evidence for direct thrombin inhibition on biomarkers.
Structured PICO
Does argatroban reduce D-dimer levels in patients with acute ischaemic stroke?
P
Population
13 patients with acute ischaemic stroke
I
Intervention
Argatroban infused continuously at 2.5 mg/h for the first 48 h, then 10 mg infused over 3 h twice a day on days 3-7. Intravenous glycerol was also administered to 5 of the 7 patients.
C
Comparator
Placebo. Intravenous glycerol was also administered to 4 of the 6 patients.
O
Outcome
D-dimer levels on days 2 and 7 after admissionsurrogate
Argatroban effectively blocks haemostatic activation, as measured by D-dimer levels, in the acute phase of ischaemic stroke.
Cite This Study
Kario et al. (1995) studied this question.